Yuan Jinghua, Chen Jingyu, Zhao Qingzhi, Xu Jialu, Li Xianwei, Zhang Yijie, Li Hairun, Chen Xintong, Zhao Ling, Zhang Xiaofen, Li Hongyu, Chen Keda
Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
Front Microbiol. 2025 Mar 13;16:1558482. doi: 10.3389/fmicb.2025.1558482. eCollection 2025.
The rapid spread of respiratory diseases, such as influenza, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Respiratory Syncytial Virus (RSV), poses significant challenges to global public health systems. Vaccination remains the most effective strategy to mitigate these threats. Baculovirus Expression Vector Systems (BEVS) have emerged as a promising platform for vaccine development, addressing key limitations of traditional methods, including complex production processes, lengthy timelines, and high costs. BEVS offers distinct advantages, such as enhanced efficacy, safety, cost-effectiveness, and scalability for large-scale manufacturing. This review highlights the application of BEVS in combating respiratory diseases by analyzing preclinical studies, clinical trials, and approved vaccines targeting these pathogens. It also examines recent advancements in BEVS technology, emphasizing its capacity to accelerate vaccine development and respond to emerging respiratory threats. By focusing on the synergy between BEVS and respiratory disease prevention, this review provides valuable insights to guide global vaccine innovation.
流感、严重急性呼吸综合征冠状病毒2（SARS-CoV-2）、中东呼吸综合征冠状病毒（MERS-CoV）和呼吸道合胞病毒（RSV）等呼吸道疾病的迅速传播，给全球公共卫生系统带来了重大挑战。疫苗接种仍然是减轻这些威胁的最有效策略。杆状病毒表达载体系统（BEVS）已成为一种有前景的疫苗开发平台，克服了传统方法的关键局限性，包括复杂的生产过程、漫长的时间线和高昂的成本。BEVS具有明显优势，如增强疗效、安全性、成本效益以及大规模生产的可扩展性。本综述通过分析针对这些病原体的临床前研究、临床试验和获批疫苗，突出了BEVS在对抗呼吸道疾病中的应用。它还审视了BEVS技术的最新进展，强调其加速疫苗开发和应对新出现的呼吸道威胁的能力。通过关注BEVS与呼吸道疾病预防之间的协同作用，本综述提供了有价值的见解，以指导全球疫苗创新。
